LEADING EXTRACELLULAR VESICLE RESEARCH TOWARDS THE NEXT GENERATION OF TREATMENTS AND DIAGNOSTICS
With
Associate Professor Joy Wolfram, Group Leader,
Australian Institute for Bioengineering and Nanotechnology,
School of Chemical Engineering, University of Queensland
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane | May 2025
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
Wolfram’s lab is currently funded by the National Breast Cancer Foundation for a four-year project aimed at understanding how breast cancer-derived vesicles evade the immune system. Collaborations with the Faculty of Medicine and hospitals in the U.S. enhance her research efforts. Additionally, partnerships with local industries in Brisbane, supported by the Medical Research Future Fund, promote academia-industry connections. Notably, funding from Health Translation Queensland allows her to compensate patient advocates who contribute valuable insights and direction to her research.
Source: Written by AUDIENCED from transcript
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Access and productivity outcomes with radiology technology in Western Sydney
In Western Sydney, there is currently significant growth accompanied by a notable need for cardiovascular support due to the prevalence of related diseases. It is estimated that the population in this area will reach 6 million by 2041.
With this population growth, there is also a pressing shortage of healthcare professionals in Australia, particularly in the field of radiology, where there are not enough radiographers, sonographers, MRI technicians, and nuclear medicine technicians.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
